are glp-1 receptor agonists approved for type 1 diabetes fda Evolution of GLP‐1 Treatment Emerging Trends in the Development

The investigation specifically showed that these drugs did not increase the risk of any fractures, confirming their safety profile in clinical practice ( 4.6 Ophthalmological effects 4.6.1 Glaucoma GLP-1R agonists exhibit anti-inflammatory and neuroprotective properties, suggesting they could also be beneficial in neurodegenerative diseases ( A recent registry-based case-control study, summarized in Table 2 , involving 1,961 patients found that the use of GLP-1R agonists is linked to a lower risk of glaucoma (Sterling et al., 2021 (79)

These agents are mainly administered subcutaneously, as they are peptide-based molecules with low bioavailability

In some cases, GLP-1s might even improve a patients eye health

10.1007/s12325-012-0045-5 126 NasrN

Thus, the different volume regulation by SGLT2-I may limit the aberrant neurohumoral and RAAS stimulation that occurs in the setting of volume depletion (54, 55)

Food and Drug Administration approvals